NCT02251184View on ClinicalTrials.gov

Pharmacokinetics of Dipyridamole Administered as Aggrenox® (Dipyridamole Extended Release Plus Aspirin) Capsule Versus Dipyridamole Immediate Release Plus Aspirin Following Alteration of Stomach pH

PHASE4CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

October 31, 2000

Primary Completion Date

November 30, 2000

Conditions
Healthy
Interventions
DRUG

Aggrenox

DRUG

Dipyridamole

DRUG

Aspirin

DRUG

Lansoprazole

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT02251184 - Pharmacokinetics of Dipyridamole Administered as Aggrenox® (Dipyridamole Extended Release Plus Aspirin) Capsule Versus Dipyridamole Immediate Release Plus Aspirin Following Alteration of Stomach pH | Biotech Hunter | Biotech Hunter